PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that, based on the preliminary review of the operating items in the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026, the Group is expected to record (i) a net profit in the range of RMB32 million to RMB49 million for the six months ended June 30, 2026, representing a decrease of 63% to 43% as compared to that of approximately RMB86.6 million for the six months ended June 30, 2025, and (ii) a profit attributable to owners of the Company in the range of RMB13 million to RMB20 million for the six months ended June 30, 2026, representing a decrease of 80% to 70% as compared to that of approximately RMB66.0 million for the six months ended June 30, 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by PW Medtech Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") (as defined in the Listing Rules).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the operating items in the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026, the Group is expected to record (i) a net profit in the range of RMB32 million to RMB49 million for the six months ended June 30, 2026, representing a decrease of 63% to 43% as compared to that of approximately RMB86.6 million for the six months ended June 30, 2025, and (ii) a profit attributable to owners of the Company in the range of RMB13 million to RMB20 million for the six months ended June 30, 2026, representing a decrease of 80% to 70% as compared to that of approximately RMB66.0 million for the six months ended June 30, 2025. Such decrease is primarily attributable to the significant decrease in product prices in the infusion set business segment, as the centralized procurement policy has been almost fully implemented and covers Beijing and other regions that account for a high proportion of the infusion set business's sales, consequently leading to a significant decrease in the segment's sales revenue and gross margin.

The Company is in the process of preparing the unaudited consolidated financial results of the Group for the six months ended June 30, 2026. The information contained in this announcement is only based on a preliminary review of the operating items in the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 and the information currently available to the Board and is not based on any figures or information which has been audited or reviewed by the Company's auditors, **and as such may be subject to finalization and adjustments arising from, among others, further review of the non-operating items in the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026**. The Company expects to publish the unaudited consolidated financial results of the Group for the six months ended June 30, 2026 on or before August 31, 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue'e ZHANG
Chairman & Chief Executive Officer

Hong Kong, August 10, 2026

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.